CURE

Bladder Cancer Treatment Is Changing: What Patients Should Know

At the 2026 NCCN Annual Meeting, CURE sat down with Dr. Thomas Flaig to discuss the rapidly evolving landscape of bladder ...

Preventing cirrhosis is the most effective way to reduce liver cancer deaths, say experts

A new update from the American Gastroenterological Association (AGA) urges stronger prevention efforts and better ...

AI identifies people with sharply elevated risk of skin cancer within 5 years

A skin cancer diagnosis can seem to arrive out of nowhere. But buried in years of health records, prescription histories, and ...
Case Western Reserve University

Researchers aim artificial intelligence at rising oral cancers with $3.3 million grant from National Cancer Institute

Case Western Reserve and partners local and global team up to better predict which patients with oral squamous cell carcinomas will need radiation or chemotherapy after surgery Researchers at Case ...
CURE

What Patients Should Know About Their Stage 1 Bladder Cancer

Receiving a diagnosis of stage 1 urothelial carcinoma (bladder cancer) can feel overwhelming, but at this stage, the cancer ...
ascopubs.org

Updates on Treatments and Management of Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma (NPC) is a unique head and neck cancer, where the endemic subtype is strongly associated with Epstein-Barr virus (EBV) infection, whereas emerging data suggest that a subset ...
Morning Overview on MSN

Bioengineered gum targets cancer-linked mouth microbes, spares others

Chewing gum is not the first thing that comes to mind when oncologists discuss head and neck cancer. But a bioengineered ...

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and ...

ImmunityBio Announces ANKTIVA(R) Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership

ANKTIVA approved for patients with certain indications of non-muscle invasive bladder cancer and non-small cell lung cancer -- Commercial availability achieved within two months of announcing MENA ...